173606-50-3

Basic information

• Product Name: BOC-10-AMINODECANOIC ACID
• Synonyms: N-TERT-BUTYLOXYCARBONYL-10-AMINO-DECANOIC ACID;BOC-10-ADC-OH;BOC-10-AMINODECANOIC ACID;N-T-BUTYLOXYCARBONYL-10-AMINO-DECANOIC ACID;N-tert-Butoxycarbonylamino-10-decanoic acid;10-(N-Boc-aMino)decanoic Acid;10-[[(1,1-DiMethylethoxy)carbonyl]aMino]decanoic Acid;Boc-10-aminodecanoic acid≥ 99% (HPLC)
• CAS NO: 173606-50-3
• Molecular Formula: C₁₅H₂₉NO₄
• Molecular Weight: 287.4
• Product Categories: Amino Acids;Amines;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 173606-50-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 429.2 °C at 760 mmHg
• Flash Point: 213.3 °C
• Appearance: /
• Density: 1.015 g/cm³
• Storage Temp.: Store at 0°C
• PKA: 4.78±0.10(Predicted)
• CAS DataBase Reference: BOC-10-AMINODECANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-10-AMINODECANOIC ACID(173606-50-3)
• EPA Substance Registry System: BOC-10-AMINODECANOIC ACID(173606-50-3)

Safety Data

• Hazardous Substances Data: 173606-50-3(Hazardous Substances Data)

Usage

Description

Boc-10-Aminodecanoic acid can be used as a PROTAC linker in the synthesis of PROTACs and other conjugation applications. Boc-10-Aminodecanoic acid is an alkane chain with terminal carboxlic acid and Boc-protected amino groups. The terminal carboxylic acid can react with primary amine groups in the presence of activators (e.g. EDC, or HATU) to form a stable amide bond. The Boc group can be deprotected under mild acidic conditions to form the free amine.

Chemical Properties

White solid

Uses

BOC-10-AMINODECANOIC ACID is an aliphatic carboxylic acid containing an amine protecting group,it is used as a reagent in the preparation of various pharmaceutical compounds.

Upstream product

• 173606-54-7 (10-hydroxydecyl)carbamic acid tert-butyl ester 
• 55362-80-6 9-bromononan-1-ol 
• 149051-24-1 ω-bromononanyl dimethyl-tert-butylsilyl ether 
• 173606-52-5 10-(tert-butyldimethylsilanyloxy)decylamine 
• 173606-51-4 10-(tert-Butyl-dimethyl-silanyloxy)-decanenitrile 
• 173606-53-6 tert-butyl (10-((tert-butyldimethylsilyl)oxy)decyl)carbamate 
• 13108-19-5 10-aminodecanoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 50530-12-6 10-bromodecanoic acid 

Downstream Products

• 279220-35-8 {9-[4-(3,5-dimethyl-benzyl)-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridin-3-ylcarbamoyl]-nonyl}-carbamic acid tert-butyl ester 
• 279220-39-2 10-amino-decanoic acid [4-(3,5-dimethyl-benzyl)-5-ethyl-6-methyl-2-oxo-1,2-dihydro-pyridin-3-yl]-amide 
• 1009-89-8 azacycloundecan-2-one 

Relevant articles and documents

TARGET PROTEIN EED DEGRADATION-INDUCING DEGRADUCER, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES RELATED TO EED, EZH2, OR PRC2, COMPRISING SAME AS ACTIVE INGREDIENT

The present invention relates to a target protein degradation-inducing Degraducer, a preparation method thereof, and a pharmaceutical composition for preventing or treating diseases related to EED, EZH2, or PRC2 comprising same as an active ingredient. A novel compound represented by formula 1, according to the present invention is a Degraducer compound that induces degradation of a target protein, i.e., embryonic ectoderm development (EED) or polycomb repressive complex 2 (PRC2), utilizing cereblon E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) E3 ubiquitin ligase, mouse double minute 2 homolog (MDM2) E3 ubiquitin ligase, and cellular inhibitor of apoptosis protein 1 (cIAP) E3 ubiquitin ligase, wherein the compound has an aspect of remarkably achieving target protein degradation-inducing activity through a ubiquitin proteasome system (UPS), and therefore there is a useful effect in that it is possible to provide a pharmaceutical composition for preventing or treating diseases or conditions related to a target protein, and a functional health food composition for preventing or improving same, comprising said compound as an active ingredient.

Peptidomimetic inhibitors of N-myristoyltransferase from human malaria and leishmaniasis parasites

N-Myristoyltransferase (NMT) has been shown to be essential in Leishmania and subsequently validated as a drug target in Plasmodium. Herein, we discuss the use of antifungal NMT inhibitors as a basis for inhibitor development resulting in the first sub-micromolar peptidomimetic inhibitors of Plasmodium and Leishmania NMTs. High-resolution structures of these inhibitors with Plasmodium and Leishmania NMTs permit a comparative analysis of binding modes, and provide the first crystal structure evidence for a ternary NMT-Coenzyme A/myristoylated peptide product complex. This journal is

COVALENT INHIBITION OF BACTERIAL QUORUM SENSING

Inhibitors of bacterial communication, such as quorum sensing, and method of use and manufacture thereof.